Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Picard Medical Inc's Competitiveness

A competitive positioning analysis and financial ratio benchmarking of Picard Medical Inc (PMI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026
Competitors Tracked
-
Publicly traded peers
Peer Group Market Share
100.00 %
vs 100.00 % a year ago
Revenue Growth Y/Y
38.62 %
Q2 2026
Net Margin
-191.60 %
Q2 2026

Key Findings: Picard Medical Inc vs Its Competitors

  • TTM: Trailing 12-month revenue of 6M vs -M combined for tracked competitors (100.0% combined share).
  • Trending: Latest-quarter revenue run-rate is accelerating (+97.5% annualized vs trailing 12 months).
  • Scale: Picard Medical Inc ranks #176 of 247 companies by market capitalization in the Medical Equipment & Supplies industry, holding 0.0% of industry market cap.
  • Peer revenue share: Picard Medical Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.

Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).

PMI Sales vs. its Competitors, Q2 2026

Picard Medical Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.

API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/PMI/competitors
https://api.csimarket.com/api/v1/companies/PMI/relationships
https://api.csimarket.com/api/v1/companies/PMI/similar
Programmatic access for models, analytics, and integration workflows.

For context: the Medical Equipment & Supplies industry grew revenue 15.1% year over year, combined, vs 38.6% for Picard Medical Inc. Picard Medical Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.

Picard Medical Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity Profitable Expanding Above Industry Growth Distressed
Picard Medical Inc No No No Yes
High-Confidence Competitors (1) 0% 0% 0% 100%
Similar-Size Competitors (10) 13% 89% 56% 25%
Similar Growth & Profitability (8) 0.00 % (0 of 8) 50.00 % (4 of 8) 50.00 % (4 of 8) 50.00 % (4 of 8)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

Market Share of the Peer Group, Q2 2026

100%market share
  • Picard Medical Inc100.0%
  • Competitors combined0.0%

Share of combined quarterly revenue of Picard Medical Inc and its 0 tracked competitors.

See Picard Medical Inc's full market share breakdown »

PMI Stock Performance relative to its Competitors

PMI Competitors (weighted) Percent change over the selected range

Picard Medical Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.
0%beat U.S.A. 500
High-Confidence
(0 of 1)
12.5%beat U.S.A. 500
Similar-Size
(1 of 8)
25%beat U.S.A. 500
Similar Growth & Profitability
(1 of 4)
Entity TTM Share Price Return
(group: median)
vs U.S.A. 500
Picard Medical Inc -49.20 % Underperformed
Competitors combined (0) 40.4% 63.2%
High-Confidence Competitors (1) 40.4% 63.2%
Similar-Size Competitors (8) 40.4% 63.2%
Similar Growth & Profitability (4) 40.4% 63.2%
Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Picard Medical Inc's competitor groups requires a Commercial License.

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

PMI Stock Performance relative to High-Confidence Competitors

PMI High-Confidence Competitors (equal-weighted, 1) Percent change over the selected range

PMI Stock Performance relative to Similar-Size Competitors

PMI Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

PMI Stock Performance relative to Similar Growth & Profitability Competitors

PMI Similar Growth & Profitability Competitors (equal-weighted, 8) Percent change over the selected range

Picard Medical Inc's Comment on Competition and Industry Peers

The total artificial heart (TAH) market includes alternative mechanical circulatory support devices such as left ventricular assist devices (LVAD), extracorporeal membrane oxygenation (ECMO) systems, and percutaneous axial flow ventricular assist devices like the Impella system. The SynCardia Total Artificial Heart is the only TAH approved for commercial use in the United States and Canada. Carmat SA has developed the Aeson total artificial heart, which holds CE mark approval in Europe; however, as of 2025, Carmat SA is undergoing financial distress and insolvency proceedings, placing its manufacturing and commercial operations at risk. The SynCardia TAH is available in two sizes (50cc and 70cc) and has been implanted in over 2,100 patients worldwide, with more than 30 years of clinical use. The competitive landscape continues to evolve, with several programs in clinical development or early commercialization stages. Regulatory approvals, clinical outcomes, physician adoption, and long-term device performance are key factors influencing competition in this sector.

Picard Medical Inc's Competitors Named by the Company

Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.
Competitor Basis Confidence Active Sources
Helen Of Troy Limited Named by the company 85% 2022 to 2026 3
CARMAT SA Named by the company 85% 2022 to 2026 3
Competitor Evidence Detail

Filing basis, confidence, active dates and source counts for Picard Medical Inc's named competitors require a Commercial License.

Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.

Get the full CSIMarket dataset: Subscribe API License